- Investing Ideas
- U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt
U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt
Results
12
Stocks with a return on equity of over 30% and a debt to equity ratio below 1.
12 companies
Gilead Sciences
Market Cap: US$166.9b
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD
US$131.10
7D
-2.4%
1Y
20.4%
Illumina
Market Cap: US$24.7b
Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
ILMN
US$164.40
7D
13.8%
1Y
102.7%
Exelixis
Market Cap: US$12.7b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$50.28
7D
0.3%
1Y
17.3%
ACADIA Pharmaceuticals
Market Cap: US$3.7b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$21.52
7D
2.0%
1Y
0.3%
ADMA Biologics
Market Cap: US$1.8b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$7.90
7D
-4.1%
1Y
-61.3%
Innoviva
Market Cap: US$1.6b
Operates as a biopharmaceutical company in the United States and internationally.
INVA
US$21.51
7D
-4.2%
1Y
6.8%
Theravance Biopharma
Market Cap: US$827.9m
A biopharmaceutical company, develops and commercializes medicines in the United States.
TBPH
US$15.94
7D
-2.6%
1Y
43.0%
CorMedix
Market Cap: US$662.1m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$8.45
7D
5.9%
1Y
-33.5%
Abeona Therapeutics
Market Cap: US$329.4m
A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
ABEO
US$5.63
7D
3.5%
1Y
-10.4%
Compugen
Market Cap: US$248.8m
A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
CGEN
US$2.46
7D
-12.1%
1Y
64.0%
Oramed Pharmaceuticals
Market Cap: US$162.5m
Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
ORMP
US$3.89
7D
-2.5%
1Y
63.4%
Vaxart
Market Cap: US$156.1m
A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.
VXRT
US$0.63
7D
-2.3%
1Y
40.0%